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Abstract 
A detailed investigation was carried out to evaluate the occurrence, persistence and fate of a range of 
micropollutants at different processing points at a full-scale water recycling plant (WRP) in 
Queensland, Australia. The WRP, which combines an advanced water treatment plant (AWTP) with a 
wastewater treatment plant (WWTP), produces high quality recycled water for industrial users. The 
concentrations of 11 pharmaceuticals from various therapeutic categories and two endocrine disrupting 
chemicals were examined in full-scale microfiltration and reverse osmosis membrane facilities. 
Salicylic acid was the most abundant analyte in the WWTP influent, with a concentration range of 11 
to 38 µg/L, followed by bisphenol A with concentrations ranging from 6 to 23 µg/L. The concentration 
of all analytes decreased on average by one order of magnitude following primary and secondary 
treatment. Gemfibrozil, primidone and carbamazepine were found to have lower removal efficiencies 
(74-78%) than other compounds during these stages, which could indicate lower biodegradability. The 
microfiltration and reverse osmosis systems were found to further lower the pollutant concentrations by 
an order of magnitude. The overall removal efficiencies in the final recycled water were above 97 %, 
resulting in product water concentrations of lower than 0.1 µg/L for most compounds. An exception to 
this finding was observed for bisphenol A, which was detected in concentrations up to 0.5 µg/L in the 
final recycled water. 
 
Keywords: Water Recycling, Reverse Osmosis (RO), Pharmaceuticals, Endocrine Disrupting 
Compounds, Wastewater. 
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1. Introduction 
In recent years, increasing attention has been paid to the presence of micropollutants such as 
pharmaceuticals and their residues in wastewater treatment plant (WWTP) effluents and the aquatic 
environment. The occurrence and fate of both organic and inorganic micropollutants in the 
environment have long been recognised as issues of public health and environmental concern. A wide 
range of organic micropollutants have been detected and identified in sewage and effluent-impacted 
water bodies, including surface waters and groundwater [1-4].  
Municipal wastewater systems are a major pathway for the disposal of pharmaceutical compounds, as 
confirmed by the fact that concentrations measured in WWTP influents reflect the amount consumed as 
measured by sales of pharmaceuticals [5]. Extensive studies have been conducted on the performance 
of wastewater treatment plants with regard to the removal of micropollutants. Results show that a 
number of pharmaceuticals are not removed effectively by conventional activated sludge treatment and 
considerable amounts of these pharmaceuticals are found in both effluent and sewage sludge [6-8]. 
Organic micropollutant removal in WWTPs is mainly accomplished by adsorption, biodegradation and 
volatilisation [9]. The chemical structure and physicochemical properties of pollutants greatly influence 
the effectiveness of these removal mechanisms. 
As concerns over the presence of micropollutants in drinking water continue to grow, the use of 
membrane processes such as reverse osmosis (RO) and nanofiltration (NF) is becoming increasingly 
common in water treatment plants. Currently, a number of Australian water recycling facilities employ 
membrane systems to treat wastewater effluents. Recent studies have examined the removal of 
emerging micropollutants by ultrafiltration (UF), NF and RO [10-13]. Most of these investigations 
were performed at bench scale using flat sheet membrane units or dead-end filtration cells, feed waters 
with high solute concentrations and short membrane operation times. Feed waters spiked with target 
solutes and virgin membranes were employed, neglecting water matrix effects and membrane fouling, 
which is commonly observed in full-scale applications. 
The removal processes of micropollutants in RO are complex and, despite many investigations, poorly 
understood. The rejection of micropollutants by RO is reported to be influenced by the dipole moment 
of compounds [14], the hydrophobicity of compounds (represented by Kow) and the compound 
molecular size [15]. Under actual conditions, it is difficult to elucidate the core mechanisms for the 
rejection of micropollutants by RO. This rejection is governed by solute-solute and solute-membrane 
interactions [16]. 
The main objective of this study was to investigate, over the period of one year, the occurrence and fate 
of micropollutants, mainly endocrine disrupting compounds (EDCs) and pharmaceutically active 
compounds (PhACs), in a metropolitan water recycling plant (WRP). The concentrations of 
micropollutants were examined in full-scale MF and RO membrane facilities treating real wastewater. 
The WRP used for this study employs a conventional activated sludge process in the WWTP phase and 
dual membranes (MF followed by RO) in the advanced water treatment plant (AWTP) phase. The 
effectiveness of micropollutant removal was investigated at both effluents of the WWTP and the 
AWTP. The target compounds were selected on the basis of previous detection in wastewater 
combined with anticipated health and environmental effects or bioaccumulation potential. 
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2. Materials and Methods 
2.1 Facility Overview 
The combined WWTP and AWTP considered in this study is located in Australia and receives mainly 
municipal wastewater. The WWTP consists of a grit removal unit and a diffused air activated sludge 
process, configured in the following sequence; anaerobic, primary anoxic, aerobic and secondary 
anoxic zones. The solids retention time (SRT) in the activated sludge process is around 13 days and the 
hydraulic retention time (HRT) is 24 hrs. The AWTP comprises of automatic backwashing 400 µm 
screens, followed by MF and RO processes as shown in Figure 1. 
 
[Figure 1] 
 
The WWTP received 152 ML/day between May 2005 and July 2006, from which it discharged 143 
ML/day of effluent water into the ocean. More than 13 ML/day were recycled through the AWTP, 
which produced 9 ML/day of very high quality water. The product water was delivered to a local 
industry, where it was mainly used as cooling tower make-up. The reject flow (MF backwash and RO 
brine), which amounted to 29 % of the AWTP influent, or approximately 3.8 ML/day, was sent back to 
the head of the WWTP. 
Sample Campaigns 
Composite raw wastewater samples and grab samples from the secondary effluent and the recycled 
water were taken as shown in Figure 1. The composite samples were collected by an automatic device 
at half hour intervals during 24 hour periods. Sample volumes collected were not proportional to the 
influent flow. All samples were collected in glass bottles (2.5 L), placed on ice and shipped overnight 
to the laboratory for testing. Sampling was carried out during the following months: May, September, 
November and December 2005, as well as February, April and June 2006. 
2.2 Target Analytes  
The one-year project was designed to evaluate the occurrence and fate of thirteen micropollutants in the 
WRP. These compounds represent two main micropollutant groups: endocrine disrupting chemicals 
(EDCs) (bisphenol A and nonylphenol) and pharmaceutically active compounds (e.g., salicylic acid, 
diclofenac and carbamazepine) as shown in  Table 1 [17, 18, 19, 20, 21, 22, 23, 24,  25]. 
 
[Table 1] 
 
The compounds selected for this study have physicochemical properties that are representative of a 
wide range of organic compounds potentially present in impaired water sources. The target 
micropollutants were classified into acidic and neutral compounds. Table 1 shows the molecular 
weight, partitioning coefficient (log Kow), dissociation constant (pKa) and solubility of the target 
micropollutants. These characteristics are used in predicting the behaviour of micropollutants under 
clinical conditions and in environmental assessments. 
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2.3 Analytical Methods 
Physicochemical Water Characterisation 
Upon receipt of samples in the laboratory, a small portion of each sample (50 to 100 mL) was poured 
into a glass bottle and allowed to settle before the physicochemical characteristics of the sample were 
measured. 
Total organic carbon contents (TOC) were determined according to Method 5310B [26] using a 
Shimadzu TOC-VCSH (Total Organic Carbon Analyzer) equipped with ASI-V autosampler [27]. The 
TOC was determined by measurement of non-purgeable organic carbon (NPOC – the fraction of TOC 
not removed by gas stripping). The nitrogen content was determined by measuring total nitrogen (TN) 
using a chemiluminescence detector with a Shimadzu Total Nitrogen Module (TNM1) coupled with the 
Shimadzu TOC–VCSH [27]. 
Ultraviolet absorption (UV) was measured at a wavelength of 254 nm according to Method 5910 [26] 
using a Shimadzu UV-Visible Spectrophotometer (model UV 1700 Phara Spec). Turbidity (T) 
measurements were performed according to Method 2130 [26] using a turbidity meter (HACH, model 
2100N, HACH, S.A/N.V, USA). The electrical conductivity (EC) of samples was measured with a 
conductivity meter as a surrogate parameter according to Method 2510 [26]. Measurement of pH was 
performed according to Method 4500-H+ [26] with a pH meter. 
Micropollutant Analysis 
Upon receipt in the laboratory, samples were filtered using three different filters: GF/D (2.7 µm) and 
GF/F (0.7 µm) Whatman filters and 0.48 µm nylon filter membranes (Alltech, Australia). Filtered 
samples were kept in amber bottles overnight at 4oC. The following day, samples were allowed to reach 
room temperature and adjusted to pH 2-3 by addition of 4 M sulphuric acid to enhance trapping of 
acidic compounds on the solid phase extraction (SPE) sorbent. MilliQ water (1 L) was also spiked with 
a standard mixture of the investigated compounds to confirm recovery of analytes. Samples were 
analysed in batches consisting of 5-6 samples, spiked samples and a blank. A detailed description of the 
method of analysis was published by Al-Rifai et al. [28]. 
For SPE, 60 mg Water Oasis HLB sorbent cartridges (Waters, Australia) were used. The SPE was 
performed on a 24-fold extraction manifold (Supelco, Visiprep 24). The SPE cartridges were 
conditioned sequentially with 5 mL methyl tert-butyl ether (MTBE), 5 mL methanol and 5 mL MilliQ 
water prior to use. Extraction of 1 L samples was carried out under vacuum at a flow rate of 
approximately 15 mL/min. After sample loading, the cartridges were washed with 3 mL (5% v/v) 
methanol in water. In order to eliminate the presence of water from the eluant, a column of anhydrous 
sodium sulphate was prepared and fitted under the SPE column before the elution procedure started. 
The SPE columns were eluted with 5 mL (10% v/v) methanol in MTBE. The elution volume was then 
evaporated to dryness at 39oC under a stream of nitrogen. 
In order to determine PhAC and EDC concentrations, a derivatization step was necessary. The extract 
residues were dissolved in 300 µL of acetonitrile and then derivatized by adding 100 µL of BSTFA 
(N,O-bis (trimethylsilyl) trifluoroacetamide) and TMCS (trimethylchlorosilane) (99:1). The analytes 
were allowed to react for 1 h at 70oC. Finally, 100 µL of fluazifop standards were added to each sample 
before injection as an instrument internal standard to confirm the accuracy of the volume of each 
sample injected onto the GC column.  
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Identification and Quantification of Compounds 
A Shimadzu-GC 17A gas chromatograph equipped with an auto-injector model AOC-20i, a mass 
detector model QP5000, a Phenomenex Zebron ZB-5 column and a Split/Splitless injector was used for 
identification and quantification of compounds. The oven temperature program was 100 oC; 30 
oC/min.; 150 oC (4 min); 3 oC/min; 195 oC; 1 oC/min; 205 oC (5 min); 30 oC/min; 250 oC (3 min). The 
injection port was maintained at 270 oC and operated in splitless mode. Helium was used as a carrier 
gas (flow rate 1 mL/min) and the interface temperature was held at 270oC. For identification of each 
analyte, three compound-specific ions were recorded in single-ion monitoring mode (SIM).  
Deuterated internal standards (acetaminophen-d4, carbamazepine-d10, gemfibrozil-d6, ibuprofen-d3, 4-n-
nonylphenol d6, phenytoin-d10 and salicylic acid-d6,) were added to the initial water samples and were 
followed through the entire analytical procedure to improve its accuracy. Quantification was carried out 
by calculation of the response factor based on the area of the target analyte and deuterated standard. 
Method Validation 
Extraction recoveries of target compounds were evaluated by determining the concentration in WWTP 
influent and effluent samples spiked with known concentrations of standards (50 ng/L). The recoveries 
vary between 70 and 92% and are shown in Table 2. Blanks (non-spiked samples) for PhACs and 
EDCs were analysed through the entire procedure with every batch and their concentrations were 
subtracted from the spiked waters. 
 
[Table 2] 
 
Standard calibration curves generated using linear regression analysis gave generally good fits to the 
data (i.e. R2 > 0.97) over the established concentration range (5-50 ng/L, excluding where this 
concentration range fell below the detection limits of a particular compound). A five-point calibration 
was performed daily, and possible fluctuations in signal intensity were checked by injection of standard 
solution at two concentrations after each 8–10 injections. 
The reproducibility of the method was studied by analysing five replicates of the recovery samples to 
ensure correct quantification. Reproducibility was calculated as errors with a 95% confidence interval, 
which was found to range from 3.4–9.5%, as shown in Table 2. Method detection limits (MDL) and 
method quantification limits (MQL) were determined from spiked water samples as the minimum 
detectable amount of analyte with a signal to noise ratio of 3 and 10, respectively. Method 
quantification limits ranged from 1-50 ng/L and are given in Table 2. 
 
3. Results and Discussion 
3.1 Characterisation of Untreated and Recycled Water 
Analysis of the raw wastewater quality was conducted along with the secondary effluent and recycled 
water analyses in order to study the treatment efficiency of both the WWTP and the AWTP. 
Physicochemical parameters measured at the three sample locations during the period of May 2005 to 
June 2006 are shown in Table 3. Large variations in measurements were observed throughout the 
sampling period (e.g., influent TOC varied from 43 to 77 mg/L), which could be associated with the 
incidence of high rainfall.  
 6
 
[Table 3] 
 
The WWTP effectively reduced TN and TOC in the wastewater by 91% and 72%, respectively (Table 
3). Nitrogen is commonly identified as a limiting nutrient in water bodies and careful control of its 
release is necessary to prevent the eutrophication of sensitive aquatic environments [29]. TN was 
further reduced to a mean concentration of 0.3-1.0 mg/L in the product water (see Table 3). Similar 
reductions in nitrogen (91%) by RO filtration were reported by Khan et al. [30]. In comparison, the 
salinity parameter, expressed as EC, was not reduced by the WWTP, but was reduced by 92% in the 
AWTP.  
A clear improvement in water quality can be observed from the WWTP effluent to the recycled water 
produced by the AWTP, in particular with respect to TOC and TN concentrations (Table 3). The 
combination of activated sludge, MF and RO proves to be an effective treatment system for the whole 
range of physicochemical parameters considered. Microfiltration allows for the removal of  colloidal 
particles, microorganisms and other particulate materials of size larger than the membrane pores (in 
this case 0.1 µm) [14]. The combination of MF with RO then allows for efficient removal of 
monovalent and multivalent ions, as well as suspended particles, colloids, turbidity and 
microorganisms (e.g., algae, bacteria and viruses). 
3.2 Occurrence of PhACs and EDCs in Influents 
Concentrations of the PhACs and EDCS in the influent and effluent of the investigated WWTP are 
summarised in Figure 2. Gemfibrozil, naproxen, acetaminophen and salicylic acid were found in all 
influent samples. Clofibric acid, phenytoin and diclofenac were the least frequently detected 
compounds with the lowest concentrations.  
 
[Figure 2] 
 
Acetylsalicylic acid (aspirin), one of the top ten pharmaceuticals dispensed in Australia [31], is easily 
degraded to salicylic acid, a more active form of the chemical [32]. Salicylic acid was found in the 
influent at concentrations significantly higher than other target compounds, ranging from 11.1×103 to 
38.5×103 ng/L. This high occurrence of salicylic acid can be linked to its high solubility (see Table 1). 
The concentrations measured are consistent with those reported in other studies [5, 33-35]. Variations 
of one order of magnitude in concentrations of salicylic acid were observed over the survey period. The 
high concentrations of salicylic acid were most likely indicative of higher rates of consumption of 
salicylic acid in conjunction with other medicines recorded during September 2005. During this time of 
the year, the recorded minimum and maximum temperatures were 10.6 oC and 23.0 oC, respectively, 
while rainfall was 14.6 mm. Decreased degradation rates of target compounds could be a result of low 
temperatures. Also, lower rainfall could diminish the effect of dilution during that time. 
Ibuprofen had the second highest concentration among the pharmaceutical analytes in this study. The 
concentrations measured are consistent with those reported by others [7, 22, 36], but are larger by one 
order of magnitude than observations by Stumpf [37] and Bendz [38]. Ibuprofen is one of the most 
commonly detected drug residues in surface waters [6]. 
Acetaminophen (paracetamol) was ranked third among the top ten most dispensed drugs in Australia, 
with 4.5 million prescriptions in the year 2003 [31]. Acetaminophen was detected in all of the 
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wastewater samples, with the highest concentrations measured in September 2005 and the lowest 
concentrations in May 2005 and April 2006. These concentrations were somewhat lower than those 
previously reported [33, 35]. 
Carbamazepine was present in the wastewater at concentrations up to 2.5×103 ng/L. Since only 2-3% of 
carbamazepine doses are excreted by the human body unmetabolised [6], the occurrence of 
carbamazepine’s primary metabolite – carbamazepine 10,11-epoxide – should be assessed in future 
investigations.  
The concentrations of PhACs in the influent may be related to higher consumption during the cold 
season of the year when more illness occurs. The months of September 2005 and June 2006 had the 
lowest mean temperatures during the sampling campaign, at 23.0oC and 21.8oC, respectively. 
Contradicting results were obtained by Coetsier et al. [39] and Castiglioni et al. [40] regarding the 
significance of seasonal variations in PhAC concentrations. Coetsier et al. [39] observed lower 
concentrations of carbamazepine in the winter months, but no significant seasonal variation in 
diclofenac and ibuprofen concentrations. Castiglioni et al. [40] reported lower ibuprofen loads to a 
sewage treatment plant during the summer period. 
Among the EDCs, bisphenol A was found in the highest concentration range of 6.3×103 to 23.0×103 
ng/L. Bisphenol A is a “slightly to moderately” toxic industrial chemical that is rapidly biodegraded in 
wastewaters and surface waters [41], but its estrogenic activity has been studied widely, making it a 
priority endocrine disrupting compound [42]. 
The concentration of nonylphenol in samples was determined as up to 1.1×103 ng/L. The amount of 
measured nonylphenol only represents 27% of the nonylphenol ethoxylates (NPnEOs – nonionic 
surfactants which are used in household and industrial applications), while the remainder is constituted 
of 61% as NP1EO (nonylphenol mono-ethoxylate) and 12% as NP2EO (nonylphenol diethoxylate) in 
the influent of WWTPs. Under anaerobic conditions, NPnEOs biodegrade to yield the most toxic 4-
substituted monoalkylphenol (4-nonylphenol) [43].  
3.3 Removal of PhACs and EDCs by WWTP processes 
Removal efficiencies of the target compounds in the WWTP were calculated as relative amounts to the 
influent concentrations using equation (1); 
 
(1) 
 
where Ci and Ce are the concentrations measured in the influent and effluent of the WWTP, 
respectively. Results of these removal efficiencies are presented in Figure 3. 
 
[Figure 3] 
 
All the acidic pharmaceuticals were removed efficiently by the WWTP, with average removals ranging 
from 77 to near 100% and variabilities of 3.5–8%, with the exception of diclofenac which was removed 
at efficiencies of 57 to near 100% with a variability of 40%. This high variability in diclofenac removal 
was related to infrequent detection at low concentrations. Furthermore, this compound has the largest 
molecular weight, the lowest aqueous solubility and is one of the most hydrophobic acidic compounds 
tested. This may affect its biodegradability. In general, the removal efficiencies found in this study 
%100
C
C -  C
i
ei ⋅=R
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were consistent with those found in other treatment plants using activated sludge as secondary 
treatment process [34, 37]. The removal efficiencies for single compounds can vary greatly from one 
WWTP to another depending on the type of treatment applied (e.g. biological and physicochemical) 
and the residence time of water in the primary sedimentation tank [44]. 
Highly variable removal efficiencies have been reported for ketoprofen and naproxen, with respective 
removals ranging from 40–65% and 40–90% in Spain [44] and from 51– near 100% and 55–98% in 
Finland [22]. In this study, ketoprofen removal ranged from 83–93% and naproxen removal from 85–
98%. This variability can be partly explained by the different hydraulic retention times of WWTPs 
[44], and by the low hydrophilic nature of naproxen and ketoprofen (log Kow ≈3) [36] and their low 
biodegradability [38]. 
Salicylic acid had the highest removal efficiencies, which can be attributed to the microbial and 
chemical degradation processes incurred during the treatment as described by Nakada [36]. 
Acetaminophen was found to be eliminated efficiently due to its biodegradability. In Germany, 
acetaminophen was detected in less than 10% of all sewage effluents and was not detected in river 
water [34]. 
Carbamazepine was found to have a relatively low removal efficiency compared to the other target 
compounds. This can be partly explained by its hydrophilic nature (log Kow <3) and chemical stability 
[45]. Clofibric acid and phenytoin were removed to below detection limit by the WWTP. However, due 
to infrequent detection at low concentrations, no conclusions can be drawn. 
Removal efficiencies for bisphenol A were above 90%, which is consistent with findings of other 
studies [9, 36]. Clara et al. [9] concluded that the nearly complete removal of bisphenol A in some 
WWTPs is mainly due to biodegradation, which is highly dependent on the activated sludge process 
SRT. No bisphenol A removal was observed in a highly loaded WWTP operating at low SRTs (1–2 
days). 
Nonylphenol had relatively low removal rates in this study, as was reported by Nakada et al. [36] and 
Clara et al. [9] for WWTPs in Austria and Japan. More recently, Clara et al. reported that 90% of the 
nonylphenol and its ethoxylates (NPnEO) were removed in the effluent of Austrian WWTPs, with 
more than 85% due to biotransformation [46]. Conversely, the removal of nonylphenol in a WWTP 
which implemented an activated sludge process was ascribed to its accumulation onto sewage sludge as 
a result of its lipophilic nature [47].  
With the introduction of the activated sludge process, the efficiency of modern sewage treatment plants 
at removing micropollutants from sewage influent has increased significantly. The removal 
mechanisms for pharmaceuticals in activated sludge processes include biological and chemical 
degradation, biotransformation, as well as adsorption to and subsequent removal in waste sludge [50]. 
A comparison of the performance of an activated sludge process and a trickling filter for wastewater 
treatment suggests that microbial activity plays an important role in PhAC removal [34]. Understanding 
of the complex biological process is currently not sufficient to tailor removal towards the broad range 
of micropollutants that are abundant in wastewater effluents.   
The results of this study show that micropollutants are not eliminated completely in sewage effluents. 
Therefore, implementing advanced technologies such as membrane processes is necessary for adequate 
removal of micropollutant compounds. 
3.4 Removal of PhACs and EDCs by MF/RO Systems 
The concentrations of PhACs and EDCs were reduced as these compounds passed through the 
treatment plant. Concentrations of target compounds in the recycled water demonstrate that the MF/RO 
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process is an effective treatment method for the removal of the targeted compounds, except for 
bisphenol A (Table 4). Bisphenol A was detected in all product water samples in concentrations 
ranging from 20-464 ng/L. These concentrations are not surprising since bisphenol A had the second 
highest concentration among the compounds found in the influent. Many researchers have investigated 
the removal of bisphenol A by NF and RO membranes [11, 51-55]. Despite the fact that these studies 
were conducted in laboratory or small-scale plants, the bisphenol A removal efficiencies observed were 
comparable to the results found in the present study.  
 
[Table 4] 
 
Clofibric acid, diclofenac and phenytoin were not detected in any product water samples. Other 
compounds (nonylphenol, gemfibrozil, ibuprofen, ketoprofen, naproxen, acetaminophen, primidone, 
salicylic acid and carbamazepine) were detected in most product water samples at a maximum 
concentration of 120 ng/L (Table 4). Recent studies have shown that the concentrations of 
micropollutants in the effluent of WWTPs are often higher than the product water concentrations 
measured in this study by more than one order of magnitude [6, 36, 44, 56]. This shows that the 
addition of a MF/RO dual membrane system to a conventional treatment plant will significantly 
increase the removal rate of PhACs detected in the wastewater. 
More than half of the analysed recycled water in this study was found to have PhACs at concentrations 
below 100 ng/L. However, no comprehensive drinking water guidelines currently exist for PhACs and 
risk assessments conducted to date have not reported that the micropollutants of PhACs detected in 
drinking water pose a significant health risk to consumers. Likewise, although EDCs are not designed 
for human consumption, no evidence exists to suggest that their presence in drinking water has adverse 
health effects. Humans are commonly exposed to PhACs and EDCs in greater doses through 
medication, food intake or application of personal care products than through drinking water [57]. 
Using a simple calculation based on our findings, the maximum possible intake of gemfibrozil from 
drinking water in a lifetime (assuming an intake of 2L per day over 70 years) would be 1.7 mg/ 
lifespan, while a single therapeutic dose of gemfibrozil is typically 100 mg or more. Much work is yet 
to be carried out to investigate the long term effects of such micropollutants taking into account the 
bioaccumulation of contaminants discharged to the environment. 
4. Conclusions 
Population growth, over consumption, climate change and severe droughts are limiting the availability 
of fresh water throughout the world, and particularly in Australia. As an attempt to meet increasing 
water demand, water authorities are increasingly considering and implementing water recycling. The 
fate of micropollutants in water resources is becoming an issue of concern as the consumption of 
micropollutants and the intensity of water recycling increases. 
The purpose of this research was to investigate the effectiveness of WWTPs and AWTPs at removing 
EDCs and PhACs. The one-year monitoring study revealed the following: 
The activated sludge, MF and RO processes proved to be a reliable combination for the removal of the 
whole range of physicochemical parameters considered. The low values achieved (i.e. EC, TN, TOC) 
demonstrate the significantly improved quality of recycled water. This high quality permits the use of 
recycled water for a number of applications in which the presence of pollutants such as salts, organic 
matter or nutrients could have undesirable effects. 
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Thirteen micropollutants (including PhACs and EDCs) were investigated over a whole year in the 
WRP. Gemfibrozil, naproxen, acetaminophen and salicylic acid were found in all WWTP influent 
samples tested, with the highest concentrations for salicylic acid. Other PhACs and EDCs were 
detected less frequently in the influent. Removal efficiencies in the activated sludge process was 
generally incomplete, with a variation from 77% to not detectable, and varied throughout the year. 
Furthermore, the MF and RO membrane processes contributed to the removal of micropollutants in the 
AWTP, such that concentrations below 0.1 µg/L were reached in the recycled water for all pollutants 
except bisphenol A.  
Although concentrations of less than 500 ng/L were measured in the product water for bisphenol A, the 
presence of this compound is a serious concern and a challenging task for researchers and practicing 
engineers using RO systems for water recycling.  
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Figure Captions 
 
Figure 1. Schematic diagram of the Wastewater Treatment Plant (WWTP) and Advanced Water 
Treatment Plant (AWTP). 
Figure 2. Removal efficiencies of PhACs and EDCs in the WWTP and AWTP. Each box 
represents one compound and each bar represents one sample. Removal percentages for both the 
WWTP and AWTP were calculated respective to the compound concentration in the WWTP 
influent. 
Figure 3. Concentrations of PhACs and EDCs (ng/L) in (A) influent and (B) effluent of the 
WWTP. 
 
 16
Figure 1 
 
Al-Rifai, J. ; Khabbaz, H. ; Schäfer, A.I. (2011) Removal of pharmaceuticals and endocrine disrupting compounds in water recycling process using reverse osmosis systems, Separation and Purification Technology, 77, 60–67.
 17
Figure 2 
 
 
 
M S N D F A J
0
60
70
80
90
100
 
R
em
ov
al
 p
er
ce
nt
ag
e
SCA
 
M S N D F A J
0
60
70
80
90
100
 
GFZ
 
 
 
M S N D F A J
0
60
70
80
90
100
 
DCF
 
 
M S N D F A J
0
60
70
80
90
100
 
R
em
ov
al
 p
er
ce
nt
ag
e
IBU
 
 
M S N D F A J
0
60
70
80
90
100
 
KPF
 
 
 
M S N D F A J
0
60
70
80
90
100
 
NPX
 
 
 
M S N D F A J
0
60
70
80
90
100
R
em
ov
al
 p
er
ce
nt
ag
e
ACM
 
 
 
M S N D F A J
0
60
70
80
90
100
 
PMD
 
 
 
M S N D F A J
0
60
70
80
90
100
 
CMZ
Month
 
 
M S N D F A J
0
60
70
80
90
100
BPA
Month
R
em
ov
al
 p
er
ce
nt
ag
e
 
 
M S N D F A J
0
60
70
80
90
100
Month
 AWTP removal
 WWTP removal
 
NP
 
 
X Axis key
M: May, 2005
S: September, 2005
N: November, 2005
D: December, 2005
F: February, 2006
A: April, 2006
J: June, 2006
 18
Figure 3 
 
 
NP
BPA
--
PHT
CMZ
--
PMD
ACM
--
NPX
KPF
IBU
DFC
--
GFZ
CLF
--
SCA
100 1000 10000
 
 
 
(A) Influent
NP
BPA
--
PHT
CMZ
--
PMD
ACM
--
NPX
KPF
IBU
DCF
--
GFZ
CLF
--
SCA
100 1000 10000
 
(B) Effluent
CF 
Al-Rifai, J. ; Khabbaz, H. ; Schäfer, A.I. (2011) Removal of pharmaceuticals and endocrine disrupting compounds in water recycling process using reverse osmosis systems, Separation and Purification Technology, 77, 60–67.
 
19
 
T
ab
le
 1
 
G
en
er
al
 c
ha
ra
ct
er
is
tic
s o
f t
ar
ge
t c
om
po
un
ds
 
C
om
po
un
d 
A
cr
on
ym
 
C
la
ss
ifi
ca
tio
n 
M
ol
 
W
ei
gh
t 
(g
/m
ol
) 
lo
g 
K
ow
 
pK
a 
W
at
er
 
So
lu
bi
lit
y 
(m
g/
L
) 
So
lu
bi
lit
y 
in
de
x a
 
A
ci
di
c 
 
 
 
 
 
 
 
Sa
lic
yl
ic
 a
ci
d 
SC
A
 
A
na
lg
es
ic
s 
18
0.
2 
13
8.
1 
(a
q)
 b
 
2.
26
[1
7]
, 
1.
19
[1
8]
 
2.
97
[1
7]
, 3
.5
[1
8]
 
22
40
[1
7]
, 5
00
0[
18
] 
SS
 
C
lo
fib
ri
c 
ac
id
 
C
LF
 
A
nt
ih
yp
er
lip
id
em
ic
s 
21
4.
5 
2.
57
[1
9]
 
N
/A
 c
 
58
3[
19
] 
V
SS
 
G
em
fib
ro
zi
l 
G
FZ
 
A
nt
ih
yp
er
lip
id
em
ic
s 
25
0.
2 
4.
39
-4
.7
7[
20
, 
21
] 
4.
42
-4
.7
[2
0,
 2
1]
 
19
[2
0,
 2
1]
 
 
D
ic
lo
fe
na
c 
D
C
F 
N
on
-s
te
ro
id
al
, 
an
ti-
in
fla
m
m
at
or
y 
31
8.
1 
29
6.
2 
(a
q)
 b
 
4.
51
[2
0]
, 
0.
7[
18
] 
4.
0-
4.
2[
18
, 
20
, 
22
] 
2.
4[
20
] 
PI
 
Ib
up
ro
fe
n 
IB
U
 
N
on
-s
te
ro
id
al
, 
an
ti-
in
fla
m
m
at
or
y 
20
6.
2 
3.
14
-4
.5
[1
7-
21
, 
23
] 
4.
9-
5.
7[
17
, 
18
, 
20
-2
2]
 
21
[1
7,
 
20
, 
21
], 
10
[1
8]
 
PI
 
K
et
op
ro
fe
n 
K
PF
 
N
on
-s
te
ro
id
al
, 
an
ti-
in
fla
m
m
at
or
y 
25
4.
3 
3.
12
[2
0,
 2
3]
 
4.
45
[2
0,
 2
2]
 
51
[2
0]
 
PI
 
N
ap
ro
xe
n 
N
PX
 
N
on
-s
te
ro
id
al
, 
an
ti-
in
fla
m
m
at
or
y 
23
0.
2 
3.
18
[2
1,
 2
3]
 
4.
15
-4
.5
[2
1,
 2
2]
 
16
[2
1]
, 1
59
[2
0]
 
PI
 
N
eu
tr
al
 
 
 
 
 
 
 
 
A
ce
ta
m
in
op
he
n 
A
C
M
 
A
na
lg
es
ic
s 
15
1.
2 
0.
46
 
-0
.8
9[
18
, 
21
] 
9.
4-
9.
7[
18
, 2
1]
 
10
0[
18
] 
V
SS
 
Pr
im
id
on
e 
PM
D
 
A
na
lg
es
ic
s 
21
8.
3 
0.
85
[2
0]
 
12
.2
6[
20
] 
50
0[
18
, 2
0]
 
V
SS
 
C
ar
ba
m
az
ep
in
e 
C
M
Z 
A
nt
ic
on
vu
ls
an
t 
23
6.
3 
2.
3-
2.
93
[1
8,
 2
1,
 
23
] 
7[
18
], 
0.
37
-2
[2
1]
 
10
[1
8]
,1
8[
21
] 
PI
 
Ph
en
yt
oi
n 
PH
T 
A
nt
ic
on
vu
ls
an
t 
25
2.
3 
2.
47
[5
] 
8.
33
[5
] 
10
[2
4]
 
 
B
is
ph
en
ol
 A
 
B
PA
 
N
on
-s
te
ro
id
al
 e
st
ro
ge
ni
c 
22
8.
3 
3.
32
[1
7,
 2
3]
 
10
.1
[2
5]
 
12
0[
17
, 2
5]
 
PI
 
N
on
yl
ph
en
ol
 
N
P 
N
on
-s
te
ro
id
al
 e
st
ro
ge
ni
c 
22
0 
4.
48
[2
3,
 2
5]
 
10
.3
[2
5]
 
5[
25
] 
PI
 
a  S
ol
ub
ili
ty
 in
de
x:
 ( P
I):
 p
ra
ct
ic
al
ly
 in
so
lu
bl
e 
<1
00
m
g/
L;
 ( V
SS
): 
ve
ry
 sl
ig
ht
ly
 so
lu
bl
e 
10
0-
10
00
m
g/
L:
 ( S
S)
: s
lig
ht
ly
 so
lu
bl
e:
 1
-1
0g
/L
 
b  (
aq
): 
aq
ue
ou
s  
c  N
/A
: n
ot
 a
pp
lic
ab
le
  
 
20
 
T
ab
le
 2
 R
ec
ov
er
ie
s o
f t
he
 ta
rg
et
 P
hA
C
s a
nd
 E
D
C
s i
n 
th
e 
in
flu
en
t 
 
R
ec
ov
er
y 
(%
) 
C
om
po
un
d 
M
in
 
M
ax
 
M
ea
n 
SD
 a 
(%
) 
M
Q
L
 b
 
(n
g/
L)
 
Sa
lic
yl
ic
 a
ci
d 
75
 
85
 
80
 
1.
7 
1 
C
lo
fib
ri
c 
ac
id
 
81
 
92
 
87
 
2.
0 
8 
G
em
fib
ro
zi
l 
80
 
90
 
86
 
1.
8 
2 
D
ic
lo
fe
na
c 
75
 
92
 
84
 
3.
0 
23
 
Ib
up
ro
fe
n 
85
 
92
 
88
 
1.
3 
6 
K
et
op
ro
fe
n 
75
 
95
 
87
 
3.
4 
9 
N
ap
ro
xe
n 
84
 
92
 
89
 
1.
4 
4 
A
ce
ta
m
in
op
he
n 
76
 
84
 
79
 
1.
4 
2 
Pr
im
id
on
e 
71
 
82
 
77
 
1.
9 
12
 
C
ar
ba
m
az
ep
in
e 
75
 
91
 
82
 
3.
4 
5 
Ph
en
yt
oi
n 
76
 
89
 
80
 
2.
4 
50
 
B
is
ph
en
ol
 A
 
85
 
92
 
89
 
1.
2 
2 
N
on
yl
ph
en
ol
 
70
 
85
 
78
 
2.
7 
1 
a  S
D
: S
ta
nd
ar
d 
de
vi
at
io
n 
(n
um
be
r o
f s
am
pl
es
: 5
) 
b  M
Q
L:
 M
et
ho
d 
qu
an
tif
ic
at
io
n 
lim
it 
 
Al-Rifai, J. ; Khabbaz, H. ; Schäfer, A.I. (2011) Removal of pharmaceuticals and endocrine disrupting compounds in water recycling process using reverse osmosis systems, Separation and Purification Technology, 77, 60–67.
 
21
 
T
ab
le
 3
 C
ha
ra
ct
er
is
tic
s o
f W
W
T
P 
in
flu
en
t a
nd
 e
ffl
ue
nt
 a
nd
 W
R
P 
pr
od
uc
t w
at
er
 
 a  N
um
be
r o
f s
am
pl
es
: 7
 
b  U
V
 a
bs
or
pt
io
n 
w
as
 m
ea
su
re
d 
at
 2
54
 n
m
 
c  S
D
: S
ta
nd
ar
d 
de
vi
at
io
n 
 
In
flu
en
t a
 
E
ffl
ue
nt
 a  
Pr
od
uc
t W
at
er
 a  
C
ha
ra
ct
er
ist
ic
s 
M
in
 
M
ax
 
M
ea
n 
± 
SD
c  
M
in
 
M
ax
 
M
ea
n 
± 
SD
c  
%
R
em
ov
al
 
M
in
 
M
ax
 
M
ea
n±
 S
D
c  
%
 R
em
ov
al
 
pH
 
7.
0 
7.
2 
7.
1 
± 
0.
1 
7.
6 
7.
9 
7.
8 
± 
0.
1 
– 
6.
2 
8.
1 
7.
3 
± 
0.
8 
– 
T
O
C
 (m
g/
L
) 
43
.0
 
77
.4
 
60
.9
 ±
 1
4.
2 
8.
7 
49
.1
 
19
.6
 ±
 1
8.
0 
72
.2
 
0.
8 
1.
8 
0.
8 
± 
0.
6 
95
.1
 
T
N
 (m
g/
L
) 
38
.6
 
52
.5
 
45
.1
± 
6.
0 
0 
6.
7 
3.
7 
± 
2.
9 
90
.9
 
0.
3 
1.
0 
0.
6 
± 
0.
3 
84
.4
 
E
C
 (m
S/
cm
) 
1.
7 
3.
1 
2.
2 
± 
0.
6 
1.
6 
2.
9 
2.
1 
± 
0.
6 
9.
4 
0.
1 
0.
2 
0.
2 
± 
0.
1 
92
.1
 
T
ur
bi
di
ty
 (N
TU
 ) 
77
.0
 
24
5.
0 
15
2.
0 
± 
77
.9
 
4.
6 
24
.6
 
11
.7
 ±
  7
.9
 
92
.5
 
0.
9 
6.
9 
3.
8 
± 
2.
2 
66
.7
 
U
V
 (1
/c
m
) b
 
0.
88
 
1.
77
 
1.
40
 ±
 0
.3
 
0.
00
 
2.
90
 
0.
92
 ±
 1
.2
2 
45
.2
 
0.
00
 
0.
14
 
0.
04
 ±
 0
.0
6 
95
.0
 
 
22
 
T
ab
le
 4
 C
on
ce
nt
ra
tio
ns
 o
f P
hA
C
s a
nd
 E
D
C
s (
ng
/L
) i
n 
re
cy
cl
ed
 w
at
er
 
 
C
om
po
un
ds
 
M
on
th
s 
SC
A
 
C
L
F 
G
FZ
 
D
C
F 
IB
U
 
K
PF
 
N
PX
 
A
C
M
 
PM
D
 
C
M
Z 
PH
T
 
B
PA
 
N
P 
M
ay
 
16
 
N
D
 a  
25
 
N
D
 
N
D
 
N
D
 
N
D
 
23
 
42
 
35
 
N
D
 
44
 
20
 
Se
p 
60
 
N
D
 
28
 
N
D
 
30
 
20
 
35
 
40
 
49
 
80
 
N
D
 
46
4 
15
 
N
ov
 
70
 
N
D
 
N
D
 
N
D
 
18
 
N
D
 
24
 
27
 
7 
50
 
N
D
 
30
 
60
 
D
ec
 
30
 
N
D
 
N
D
 
N
D
 
50
 
10
 
39
 
N
D
 
N
D
 
20
 
N
D
 
20
 
N
D
 
Fe
b 
30
 
N
D
 
N
D
 
N
D
 
55
 
N
D
 
N
D
 
N
D
 
N
D
 
N
D
 
N
D
 
30
0 
N
D
 
A
pr
 
20
 
N
D
 
50
 
N
D
 
50
 
N
D
 
50
 
20
 
40
 
N
D
 
N
D
 
12
1 
N
D
 
Ju
n 
20
 
N
D
 
12
0 
N
D
 
20
 
44
 
55
 
44
 
29
 
35
 
N
D
 
45
0 
54
 
M
ea
n 
b  
35
 
N
D
 
56
 
N
D
 
37
 
25
 
41
 
31
 
33
 
44
 
N
D
 
20
4 
37
 
St
an
da
rd
 d
ev
ia
tio
n 
21
 
N
D
 
44
 
N
D
 
16
 
17
 
12
 
11
 
16
 
23
 
N
D
 
19
7 
23
 
a  N
D
: n
ot
 d
et
ec
te
d 
b  M
ea
n 
of
 p
os
iti
ve
 d
et
ec
tio
n 
   
Al-Rifai, J. ; Khabbaz, H. ; Schäfer, A.I. (2011) Removal of pharmaceuticals and endocrine disrupting compounds in water recycling process using reverse osmosis systems, Separation and Purification Technology, 77, 60–67.
